Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Mar;25(3):623-628.
doi: 10.1093/annonc/mdt532. Epub 2014 Jan 7.

Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study

G Houvenaeghel  1 , A Goncalves  2 , J M Classe  3 , J R Garbay  4 , S Giard  5 , H Charytensky  6 , M Cohen  7 , C Belichard  8 , C Faure  9 , S Uzan  10 , D Hudry  11 , P Azuar  12 , R Villet  13 , P Gimbergues  14 , C Tunon de Lara  15 , M Martino  7 , E Lambaudie  7 , C Coutant  11 , F Dravet  3 , M P Chauvet  5 , E Chéreau Ewald  16 , F Penault-Llorca  17 , B Esterni  18
Affiliations
Clinical Trial

Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study

G Houvenaeghel et al. Ann Oncol. 2014 Mar.

Abstract

Background: A subgroup of T1N0M0 breast cancer (BC) carries a high potential of relapse, and thus may require adjuvant systemic therapy (AST).

Patients and methods: Retrospective analysis of all patients with T1 BC, who underwent surgery from January 1999 to December 2009 at 13 French sites. AST was not standardized.

Results: Among 8100 women operated, 5423 had T1 tumors (708 T1a, 2208 T1b and 2508 T1c 11-15 mm). T1a differed significantly from T1b tumors with respect to several parameters (lower age, more frequent negative hormonal status and positive HER2 status, less frequent lymphovascular invasion), exhibiting a mix of favorable and poor prognosis factors. Overall survival was not different between T1a, b or c tumors but recurrence-free survival was significantly higher in T1b than in T1a tumors (P = 0.001). In multivariate analysis, tumor grade, hormone therapy and lymphovascular invasion were independent prognostic factors.

Conclusion: Relatively poor outcome of patients with T1a tumors might be explained by a high frequency of risk factors in this subgroup (frequent negative hormone receptors and HER2 overexpression) and by a less frequent administration of AST (endocrine treatment and chemotherapy). Tumor size might not be the main determinant of prognosis in T1 BC.

Keywords: T1N0M0; adjuvant systemic therapy; breast cancer; prognosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Recurrence-free survival according to tumor stage.
See this image and copyright information in PMC

References

    1. Fracheboud J, Otto SJ, van Dijck JA, et al. Decreased rates of advanced breast cancer due to mammography screening in the Netherlands. Br J Cancer. 2004;91:861–867. - PMC - PubMed
    1. Bland KI, Menck HR, Scott-Conner CE, et al. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998;83:1262–1273. - PubMed
    1. Leitner SP, Swern AS, Weinberger D, et al. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0) Cancer. 1995;76:2266–2274. - PubMed
    1. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol. 2007;25:4952–4960. - PubMed
    1. Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001;93:112–120. - PubMed